STipe Therapeutics A/S (Aarhus, Denmark) focuses on harnessing the innate immune system to battle cancer.
The company has developed first-in-class drugs targeting intracellular protein-protein interactions of the STING Pathway; a major driver of innate immunity, and regulator of tumorigenesis and autoimmune disorders. The company has identified and validated compounds that sensitizes the STING pathway and by this modulates the tumor microenvironment to support a potent anti-tumoral response.
For more information, please contact:
Phone: +45 2481 6967